Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Syros Pharmaceuticals, Inc. (SYRS)
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syros.com
Company Research
Source: Business Wire
– Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q 2024; Company to Host HR-MDS-focused Webcast Event with Medical Experts on June 25, 2024 –– Received FDA Fast Track Designation for Tamibarotene for the Treatment of Unfit AML; Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 3Q24 –-- Management to Host Conference Call at 8:30 AM ET Today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.“In 2024, we are acutely focused on execution across clinical and pre-commercial activities as we advance tamibarotene toward critical milestones, including additional data from the Phase 2 SELECT-AML-1 trial in the third quarter and pivotal CR da
Show less
Read more
Impact Snapshot
Event Time:
SYRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRS alerts
High impacting Syros Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SYRS
News
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week [Yahoo! Finance]Yahoo! Finance
- Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression [Yahoo! Finance]Yahoo! Finance
- Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene OverexpressionBusiness Wire
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
SYRS
Earnings
- 5/14/24 - Beat
SYRS
Sec Filings
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- SYRS's page on the SEC website